Lineage (LCTX) Announces Appointment of Dr. Dipti Amin to Its Board of Directors
- Wall St weighed down by inflation jitters
- AT&T (T) to Merge Media Assets with Discovery (DISCA) in Blockbuster Deal, Valuation Estimated at $150 Billion
- Bitcoin (BTC) Hits 3-Month Lows Before Bouncing as Musk Confirms Tesla Has Not Sold Any BTC
- Morgan Stanley Sees a Path for Amazon.com (AMZN) to Hit $6,000 In the Next 12 Months
- Bill Gates Left Microsoft (MSFT) Board Amid Probe Into 'Intimate Relationship': WSJ
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced the appointment of Dr. Dipti Amin, MBBS, FFPM, MRCGP, DCPSA, DCH, DRCOG, DGM, to the Company’s Board of Directors, effective as of April 20, 2021. Dr. Amin is an experienced Non-Executive Director and a medically trained senior executive with broad expertise in medicine, pharmacology, healthcare, research, and product development. Dr. Amin has more than 26 years of experience within the pharmaceutical sector and is accomplished across diverse functional areas including clinical research, drug development, ethics and compliance, and commercial operations. She currently serves as a Non-Executive Director on the board of directors of Buckinghamshire Healthcare National Health Service Trust and the University of Hertfordshire in the UK.
“We are honored that Dr. Amin will be joining Lineage’s Board of Directors at this important time in the advancement of our mission to become the leading allogeneic cell transplant company,” stated Al Kingsley, Lineage’s Chairman of the Board. “Dr. Amin has had leadership responsibility for many aspects of pharmaceutical product development and clinical trials and has worked with numerous sponsors on countless product candidates while at Quintiles (now IQVIA). We believe her breadth of experience in clinical research and drug development, as well as her medical expertise and practical operational experience, will be particularly valuable to our Board and management team as Lineage continues to advance its three product candidates toward later stage clinical trials. We look forward to her support in guiding our corporate, product, and clinical strategy as we position ourselves for years of growth in the field of cell therapy.”
“Lineage’s clinical-stage programs and platform technologies have the potential to transform outcomes for patients suffering from serious medical conditions,” stated Dr. Amin. “I am excited about the opportunity to contribute to the Company’s future growth. I particularly look forward to helping guide the advancement of Lineage’s novel cell therapy product candidates toward later-stage clinical trials and the execution of other potentially valuable development activities, with an ultimate focus on transforming the lives of patients and creating value for the Company’s shareholders.”
Dipti Amin, MBBS, FFPM, MRCGP, DCPSA, DCH, DRCOG, DGM
Dipti Amin is an experienced Non-Executive Director and medically trained senior executive with a passion for high quality pharmaceutical research and healthcare, and extensive commercial, leadership, operational experience, in the private & public sectors, in medicine, pharmacology and the highly-regulated healthcare & research sectors, as well as compliance expertise. Over a span of more than 26 years, Dr. Amin has held positions of operational and strategic responsibility within Pharmaceutical Services at the C-suite and Board level, delivering consistently on growth, quality, customer, employee and process targets. Her broad experience covers Clinical Pharmacology, ethical issues in clinical research, drug development, ethics and compliance programs as well as leadership and management of large, multi-functional, multi-geography, global groups to deliver value-added, efficient growth and achieving business turnarounds. Dr. Amin has extensive international operational experience, including in the U.S., India, East Asia and Africa.
Dr. Amin spent more than 20 years at Quintiles Transnational (now IQVIA), the world’s largest provider of biopharmaceutical development & commercial outsourcing services. During her tenure, Dr. Amin served in a number of senior executive roles including: Compliance; Ethics & Quality; Drug Safety and Medical Affairs; Medical and Scientific Services; Regulatory Affairs, Medical Writing and Strategic Drug Development; and Clinical Development and Scientific Operations. Dr. Amin has successfully developed strategy and helped grow the P&L, sales & management for business units generating up to $600 million in revenue, while employing internationally based, multi-functional groups of highly qualified personnel. Dr. Amin is an Honorary Lecturer in Clinical Pharmacology at Guy’s, King’s, and St. Thomas’ Hospitals Medical & Dental Schools. Dr. Amin has also served on the Boards of Cambridge Innovation Capital and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, on the Innovation Board and Medical Expert Network of the Association of the British Pharmaceutical Industry, on a Department of Health Multi-centre Research Ethics Committee, on the Emerging Science and Bioethics Advisory Committee of the Dept. of Health, and on the Board of Governors of Heathfield School for Girls (The Girls’ Day School Trust).
Dr. Amin received her MB, BS (Bachelor of Medicine; Bachelor of Surgery) from Guys Hospital and St Thomas’ Hospitals (now GKT) Medical School in 1987. She holds the following certifications: DRCOG (Diploma of the Royal College of Obstetrics & Gynaecologists), DGM (Diploma in Geriatric Medicine of the Royal College of Physicians), MRCGP (Member of the Royal College of General Practitioners), DCH (Diploma in Child Health of the Royal College of Physicians), DCPSA (Diploma in Clinical Pharmacology), MFPM (Awarded Membership by Distinction of the Faculty of Pharmaceutical Medicine) and FFPM (Fellow of the Faculty of Pharmaceutical Medicine). Her clinical research work has been widely published in professional journals and textbooks, and she is a recognized presenter at international conferences.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Henry Schein (HSIC) Reports Election of Reed V. Tuckson, M.D., FACP to Board
- Lineage Reports First Quarter 2021 Financial Results and Highlights Significant Progress With All Three Clinical Programs
- Humanigen Inc. (HGEN) and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab
Create E-mail Alert Related CategoriesBoard Changes
Related EntitiesTwitter, AdCom
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!